News Releases

Mallinckrodt To Present At Deutsche Bank Healthcare Conference

DUBLIN, April 22, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Wednesday, May 6, 2015, at the Deutsche Bank 40th Annual Health Care Conference at the InterContinental Boston hotel in Boston, Mass.

Mark Trudeau, President and Chief Executive Officer; Matthew Harbaugh, Senior Vice President and Chief Financial Officer; and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a session scheduled to begin at 1:30 p.m. Eastern / 10:30 a.m. Pacific.

Individuals who cannot attend the meeting in person can find webcast information on Mallinckrodt's Investor Relations website or at: A replay will also be available following the meeting.

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. As of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. To learn more about Mallinckrodt, visit

Rhonda Sciarra
Communications Manager

Meredith Fischer
Senior Vice President, Communications and Public Affairs

Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

John Moten
Vice President, Investor Relations

Logo -


To view the original version on PR Newswire, visit:

SOURCE Mallinckrodt Pharmaceuticals